Adult obesity is a risk factor for infection-related hospitalizations and mortality, with about 10% of infection-related deaths due to obesity in 2023.

The United States Food and Drug Administration recently approved Uplizna ® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) among adults who are antiacetylcholine receptor ...

Fasinumab 1 mg every 4 weeks led to greater clinical improvements compared with naproxen or placebo in patients with ...

Among patients maintaining a low-fat or low-carb diet, coronary heart disease risk was lowest among those with a healthy diet pattern.

Initiation of hormone therapy after age 65 years is tied to significantly increased risks for cancer and vascular events.

Discrimination was linked to increased systemic lupus erythematosus symptom burden, mediated by symptoms of depression and ...

Patients with IIMs who were AMA-M2 positive vs negative had a greater risk for cardiac involvement, though overall survival was similar between groups.

PTC Therapeutics announced it will withdraw the ataluren NDA for nmDMD, citing FDA concerns regarding the evidence of the agent's effectiveness.

Youth overweight, obesity, and severe obesity were highly prevalent among children and young adults in the United States in 2024.

Time-restricted feeding can reduce clinical disease activity in Crohn disease in people with overweight or obesity, including those in remission.

Atrasentan shows clinically meaningful effects on kidney function in IgA nephropathy patients, including those receiving SGLT2 inhibitors.

Use of medications for mental health and behavioral conditions among children and young adults increased steadily for 2 decades.